Teladoc Health (NYSE:TDOC) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Teladoc Health (NYSE:TDOC) posted its earnings results on Wednesday. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05, FiscalAI reports. The business had revenue of $642.27 million during the quarter, compared to analysts’ expectations of $635.33 million. Teladoc Health had a negative return on equity of 9.09% and a negative net margin of 7.92%.Teladoc Health’s revenue for the quarter was up .3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.28) EPS. Teladoc Health updated its Q1 2026 guidance to -0.450–0.350 EPS and its FY 2026 guidance to -1.100–0.700 EPS.

Here are the key takeaways from Teladoc Health’s conference call:

• Consolidated Q4 revenue was $642M with adjusted EBITDA of $84M (13% margin); year-end cash of $781M, free cash flow of $167M and retirement of $550M of convertible debt left net debt under 0.8x, strengthening liquidity and leverage.
• The Integrated Care segment showed momentum — Q4 revenue of $409M (+4.7% YoY) and adjusted EBITDA up 23% to $65M (16% margin) while chronic care enrollment and international growth contributed to full‑year strength.
• Company is investing in AI and data platforms (notably Pulse and Prism) to drive clinical personalization, care-team efficiency, and product differentiation across chronic care, virtual care and hospital solutions.
• BetterHelp revenue declined (Q4 $233M; FY $950M) and average paying users fell, but Q4 adjusted EBITDA improved and management plans to scale insurance revenue to $75M–$90M in 2026 with an exit run rate >$100M — a turnaround path with execution risk.
• 2026 guidance calls for consolidated revenue of $2.47B–$2.59B (roughly flat at midpoint), consolidated adjusted EBITDA of $266M–$308M, lower stock‑based comp (<$60M) and a two‑phase plan to address 2027 convertible notes to materially reduce gross debt.

Teladoc Health Trading Down 1.1%

Shares of TDOC stock traded down $0.06 during mid-day trading on Friday, hitting $5.29. The company’s stock had a trading volume of 2,482,551 shares, compared to its average volume of 6,858,849. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $9.94. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70. The company’s fifty day simple moving average is $6.03 and its 200-day simple moving average is $7.21. The company has a market cap of $939.17 million, a PE ratio of -4.64 and a beta of 2.12.

Wall Street Analysts Forecast Growth

TDOC has been the subject of a number of recent research reports. Citigroup reduced their price target on Teladoc Health from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Friday, January 9th. Canaccord Genuity Group decreased their target price on shares of Teladoc Health from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday. Stifel Nicolaus reduced their price target on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a research note on Monday, December 29th. Finally, Wells Fargo & Company reduced their price objective on Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday. Four analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $7.80.

Insiders Place Their Bets

In other news, insider Carlos Nueno sold 3,897 shares of Teladoc Health stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total value of $29,188.53. Following the completion of the sale, the insider owned 27,175 shares in the company, valued at $203,540.75. The trade was a 12.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Adam C. Vandervoort sold 5,720 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $42,842.80. Following the transaction, the insider directly owned 80,732 shares in the company, valued at approximately $604,682.68. This represents a 6.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 33,288 shares of company stock valued at $251,684. Company insiders own 0.58% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Entropy Technologies LP bought a new stake in Teladoc Health during the 3rd quarter valued at $133,000. Quantitative Investment Management LLC increased its position in shares of Teladoc Health by 40.3% during the third quarter. Quantitative Investment Management LLC now owns 17,799 shares of the health services provider’s stock worth $137,000 after acquiring an additional 5,114 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Teladoc Health by 58.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 22,481 shares of the health services provider’s stock worth $196,000 after acquiring an additional 8,254 shares during the last quarter. Corient Private Wealth LLC lifted its position in Teladoc Health by 30.4% in the 2nd quarter. Corient Private Wealth LLC now owns 17,180 shares of the health services provider’s stock valued at $149,000 after acquiring an additional 4,004 shares in the last quarter. Finally, Manhattan West Asset Management LLC bought a new position in Teladoc Health in the 2nd quarter valued at about $100,000. 76.82% of the stock is owned by institutional investors.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 beat and improved EPS — Teladoc reported Q4 revenue of $642.3M and a GAAP loss of $0.14/sh, beating consensus on both revenue and EPS (narrower loss vs. the prior year). The surprise on the bottom line and revenue outperformance is the main driver for the intraday rally. Read More.
• Positive Sentiment: Segment strength helped offset weaknesses — Management highlighted international growth and Integrated Care strength, which offset weakness at BetterHelp; investors viewed these operating improvements as evidence of stabilization. Read More.
• Positive Sentiment: Selective analyst upgrades and support — Bank of America upgraded TDOC from Neutral to Buy with a $7 PT, and some firms (e.g., Canaccord) kept buy ratings even after trimming targets, providing runway for bullish views. Those supportive notes likely helped buying interest. Read More.
• Neutral Sentiment: Company guidance and 2026 revenue outlook — Teladoc provided FY2026 revenue guidance roughly in the $2.47B–$2.59B range and an updated slide deck/transcript; the revenue range gives a roadmap for growth but is tied to the EPS guidance that disappointed. Read More.
• Negative Sentiment: Cautious EPS guidance weighed on sentiment — Management set Q1 EPS guidance (-$0.45 to -$0.35) and FY2026 EPS guidance (-$1.10 to -$0.70) that were weaker than street expectations, and Q1 revenue guidance came in below consensus — a clear near‑term headwind. Read More.
• Negative Sentiment: Multiple price‑target cuts and cautious analyst notes — Several firms trimmed targets (BMO, TD Cowen, Wells Fargo, Stifel, Leerink) and some moved to Market Perform/Hold, creating mixed analyst positioning despite a few buy calls; this likely capped upside. Read More.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.